Galera Therapeutics Inc. (GRTX)
0.03
-0.00 (-12.02%)
At close: Mar 25, 2025, 10:48 AM
0.04
4.48%
After-hours: Mar 25, 2025, 04:00 PM EDT
-12.02% (1D)
| Bid | 0.03 |
| Market Cap | 2.53M |
| Revenue (ttm) | 122.09K |
| Net Income (ttm) | -27.21M |
| EPS (ttm) | -0.29 |
| PE Ratio (ttm) | -0.12 |
| Forward PE | -0.04 |
| Analyst | n/a |
| Ask | 0.04 |
| Volume | 11,361 |
| Avg. Volume (20D) | 189,264 |
| Open | 0.03 |
| Previous Close | 0.03 |
| Day's Range | 0.03 - 0.03 |
| 52-Week Range | 0.02 - 0.24 |
| Beta | 2.06 |
About GRTX
Galera Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule superoxide dismutase mimetic, which has completed Phase III clinical trial for the treatment of radiotherapy induced severe oral mucositis in patients with head and neck cancer...
Industry Biotechnology
Sector Healthcare
IPO Date Nov 7, 2019
Employees 7
Stock Exchange NASDAQ
Ticker Symbol GRTX
Website https://www.galeratx.com
9 months ago
-32.59%
Galera Therapeutics shares are trading lower after...
Unlock content with
Pro Subscription
1 year ago · proactiveinvestors.com
Galera Therapeutics shares plummet after FDA rejects drug for cancer treatment side effectGalera Therapeutics shares plunged by almost 85% after the clinical-stage biopharmaceutical company revealed its New Drug Application for its investigational therapeutic avasopasem manganese (avasopas...
